65,437 trials
Metastatic Malignant Neoplasm in the Liver · Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) — 0; 0; 8; 5 Participants
Knee Osteoarthritis · Total Knee Arthroplasty · Knee
Primary: Medial AP Translations, in mm — -6.9; -0.2; -4.4 millimeters
Healthy
Primary: DASS-21 — 2.9; 2.7; 4.5 units on a scale
Infant, Newborn · Infant, Premature · Pain Perception
Primary: Change in Nociception-specific Brain Activity — 17.9; 9.9; 11.5; 10.2 microvolts*milliseconds — p=<0.001
Alzheimer Disease
Primary: Number of Participants With an Improvement of ≥ 4 Points on the ADAS-cog/11 — 0 responders
Cancer
Primary: Symptom Severity Index- Comparison of Two Groups Created by First Randomization — 26.28; 26.55; 12.02; 11.19 units on a scale — p=.81
Healthy · Gait, Frontal
Primary: Pelvic Obliquity — -0.55; -0.83; -1.2; -0.7 degrees — p=0.05
Alcohol Use, Unspecified
Primary: Alcohol-related Problems — 2.75; 4.88 units on a scale — p=.0173
Heart Failure With Left Bundle Branch Block
Primary: Combined Endpoint of All-cause Mortality and Intervention for Heart Failure Decompensation — 430; 470 Participants — p=0.077
Respiratory Tract Infection · Respiratory Syncytial Virus
Primary: Percentage of Participants Who Experienced At Least One Solicited Injection Site Adverse Event (AE) — 3; 3; 3; 2 Participants
Spinal Cord Injuries
Primary: Electromyographic Responses (Active)
Neoplasms
Primary: The Maximum Tolerated Dose (MTD)/Optimal Biological Dose (OBD) of BI 905681 — NA milligram/kilogram
Contact Lens · Astigmatism of Both Eyes
Primary: Subjective Vision in Contact Lenses Assessed Using a 1 to 10 Scale After 16 Hours of Wear in One Day (After up to 14 Days of Wear) — 9 units on a scale
Sexual Behavior · Alcohol Drinking · Sexual Aggression
Primary: Mean Score of Sexual Risk Intentions — 2.35; 1.67; 2.15; 1.37 score on a scale — p=<.01
Presbyopia
Primary: Percentage of Subjects With a ≥ 3-line Gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8, 1 Hour Post-Dose 1…